This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Cephalon, Inc.. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Paul Ayton - Innovator in Immunoconjugate Technology
Introduction
Paul Ayton is a notable inventor based in San Francisco, CA. He has made significant contributions to the field of immunology, particularly through his innovative work on immunoconjugates. His research focuses on enhancing the efficacy of immunotherapies, which are crucial in the fight against various diseases.
Latest Patents
Paul Ayton holds a patent for "Anti-pd-1 antibody-attenuated IL-2 immunoconjugates and uses thereof." This patent discloses modified human interleukin-2 (hIL-2) proteins and human antibody molecules that specifically bind to human programmed cell death protein-1 (hPD-1). The immunoconjugates developed from this research have promising applications in therapeutic settings.
Career Highlights
Throughout his career, Paul has been associated with Cephalon, Inc., where he has been instrumental in advancing research and development in immunotherapy. His work has led to significant advancements in the understanding and application of immunoconjugates in clinical settings.
Collaborations
Paul has collaborated with esteemed colleagues, including David S Wilson, Jr. and Kim Tran Yap. These partnerships have fostered a collaborative environment that enhances innovation and drives research forward.
Conclusion
Paul Ayton's contributions to immunoconjugate technology exemplify the impact of innovative thinking in the field of medicine. His work continues to pave the way for advancements in immunotherapy, showcasing the importance of research and collaboration in achieving breakthroughs.